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Background: Screening for serum cryptococcal antigen (CrAg)
may identify those at risk for disseminated cryptococcal disease
(DCD), and preemptive ﬂuconazole treatment may prevent progression
to DCD. In August 2012, the Western Cape Province (WC), South
Africa, adopted provider-initiated CrAg screening. We evaluated the
implementation and effectiveness of this large-scale public-sector
program during its ﬁrst year, September 1, 2012–August 31, 2013.
Methods: We used data from the South African National Health
Laboratory Service, WC provincial HIV program, and nationwide
surveillance data for DCD. We assessed the proportion of eligible
patients screened for CrAg (CrAg test done within 30 days of CD4
date) and the prevalence of CrAg positivity. Incidence of DCD
among those screened was compared with those not screened.
Results: Of 4395 eligible patients, 26.6% (n = 1170) were
screened. The proportion of patients screened increased from
15.9% in September 2012 to 36.6% in August 2013. The prevalence
of positive serum CrAg was 2.1%. Treatment data were available for
13 of 24 CrAg-positive patients; 9 of 13 were treated with
ﬂuconazole. Nine (0.8%) incident cases of DCD occurred among
the 1170 patients who were screened for CrAg vs. 49 (1.5%) incident
cases among the 3225 patients not screened (P = 0.07).
Conclusions: Relatively few eligible patients were screened under
the WC provider-initiated CrAg screening program. Unscreened
patients were nearly twice as likely to develop DCD. CrAg screening
can reduce the burden of DCD, but needs to be implemented well.
To improve screening rates, countries should consider laboratory-
based reﬂexive screening when possible.
Key Words: South Africa, cryptococcal meningitis, cryptococcal
antigen, CrAg, screening, ﬂuconazole prophylaxis, prevention
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INTRODUCTION
Cryptococcal disease is a leading cause of mortality
among people living with HIV (PLHIV) with advanced
immunosuppression in sub-Saharan Africa.1 Given the lim-
ited availability of medications such as amphotericin B and
ﬂucytosine to treat disseminated cryptococcal disease,2,3 and
mortality rates of 30%–70% associated with this disease,4
prevention of cryptococcal disease has emerged as an
important strategy to reduce AIDS-associated mortality.5
Cryptococcal antigen (CrAg) is detectable in the serum
a median of 22 days (range: 5–234) before symptoms of
meningitis appear,6 suggesting that screening for antigenemia
during the asymptomatic phase, before onset of disseminated
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disease, is possible. Preemptive treatment with ﬂuconazole
for those with asymptomatic antigenemia may prevent pro-
gression to meningitis and other forms of disseminated
disease. In 2009, a retrospective study in South Africa
showed a serum CrAg prevalence of 6% among antiretroviral
therapy (ART)-naive patients with CD4+ T-lymphocyte
(CD4) counts ,100 cells per microliter. More than a quarter
(28%) of those who screened CrAg positive and did not
receive preemptive ﬂuconazole therapy went on to develop
CM and 34% died, compared with no cases of meningitis and
an 11% mortality rate among those who screened CrAg
negative.7 In 2010, a small study from Uganda showed that
71% of CrAg-positive patients who were treated with
ﬂuconazole survived to 30 months compared with 0% among
those not treated with ﬂuconazole. Based on this and other
evidence, the World Health Organization (WHO) issued rapid
advice guidelines in 2011 conditionally recommending
screening of all ART-naïve patients with CD4 counts less
than 100 cells per microliter for presence of cryptococcal
antigenemia and preemptive ﬂuconazole treatment of those
who screened CrAg positive before ART initiation in high
CrAg prevalence settings.8
In April 2012, South Africa’s National Strategic Plan on
HIV, sexually transmitted infections (STIs) and tuberculosis
(TB) was revised to include guidance on CrAg screening and
preemptive treatment.9 Four months later, Western Cape became
the ﬁrst province in South Africa to adopt CrAg screening and
treatment as part of the HIV care package in the public sector.
The approach was provider-initiated screening, with the program
relying on individual health care providers to order the CrAg test
for eligible patients once their CD4 count was known.
We evaluated the implementation of this public sector
provider-initiated CrAg screen-and-treat intervention in the
Western Cape from September 1, 2012 to August 31, 2013,
the ﬁrst year of the screening program. We also evaluated the
effectiveness of CrAg screening by assessing the difference in
incidence of disseminated cryptococcal disease between pa-
tients who were screened vs. those eligible but not screened.
METHODS
Study Setting
An estimated 260,000 adults are living with HIV
infection in the Western Cape and HIV prevalence is nearly
4%.10 ART was initiated in over 31,000 patients in 2012 in
the province; slightly less than 20% of these patients
presented with a CD4 count of ,100 cells per microliter.11
All patients with a new HIV diagnosis are advised to undergo
clinical staging and to obtain a CD4 cell count within 1 week
of initial presentation. ART is initiated for all patients with
CD4 cell count ,350 cells per microliter (guidelines changed
in 2015 to include all patients with CD4 cell count,500 cells
per microliter); those with CD4 cell count ,100 cells per
microliter are given higher priority for treatment initiation.
In August 2012, the Western Cape HIV/AIDS, STI, and
TB (HAST) directorate sent a circular to all (approximately 200)
provincial ART facilities with 10 updates to antiretroviral
treatment guidelines. This circular also contained CrAg screening
guidance, instructing clinicians to offer CrAg screening to HIV-
infected adults not currently on ART who present with a CD4
cell count ,100 cells per microliter; ﬂuconazole treatment was
recommended for all CrAg-positive asymptomatic patients, and
referral for LP was recommended for symptomatic patients
(headache). No speciﬁc clinical training on the CrAg screen-and-
treat initiative was offered at that time. Providers were
responsible for ordering a separate blood draw for CrAg testing
for a patient with a CD4 cell count ,100 cells per microliter.
Providers did not receive any feedback on how well they were
doing with ordering CrAg tests on eligible patients.
Laboratory Methods
Venipuncture was performed and blood samples,
collected in a red-top, plain nonserum separator tube, were
transported to one of 3 clinical laboratories in the province.
The laboratories used the Cryptococcal Antigen Latex
Agglutination (LA) System (Meridian Bioscience, Inc.,
Cincinnati, OH) or the Cryptococcus Antigen Latex Agglu-
tination Test System (ImmunoMycologics, Norman, OK) to
perform CrAg testing. All patients in the evaluation were
tested using LA because the CrAg lateral ﬂow assay (LFA)
was not approved for use in South Africa at the initiation of
the screening program.
Study Design
This was a retrospective cohort study of the CrAg
screen-and-treat initiative in the Western Cape Province. The
primary study outcomes were the proportion of eligible patients
screened for CrAg and the prevalence of CrAg positivity
among those who were screened. The secondary outcome was
the incidence of laboratory-conﬁrmed disseminated cryptococ-
cal disease among those who were screened compared with
those who were not screened. As a third component of the
analysis, we examined all cases of disseminated cryptococcal
disease among PLHIV in the Western Cape between Septem-
ber 1, 2012 and August 31, 2013 and assessed CD4 count and
ART status at the time patients presented with cryptococcal
disease to understand which interventions (eg, earlier HIV
diagnosis, ART initiation, CrAg-screen-and-treat, etc.) would
best address the burden of cryptococcal disease.
Data Sources
No speciﬁc monitoring and evaluation system was in
place for the CrAg screening program in the Western Cape.
Therefore, data for this study were obtained from several
large, pre-existing provincial and national databases.
• The National Health Laboratory Services (NHLS)’s Cor-
porate Data Warehouse, a centralized repository for
diagnostic laboratory results generated by NHLS laborato-
ries throughout South Africa: we extracted all CD4 counts
(during 2007–2013) and serum CrAg tests performed in the
Western Cape during the study period (September 1, 2012–
August 31, 2013) from this source.
• TIER.Net, an electronic, province-wide database used in
the majority of Western Cape provincial clinics captures
Vallabhaneni et al J Acquir Immune Defic Syndr  Volume 72, Number 2, June 1, 2016
e38 | www.jaids.com Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
patient ART status, including ART start date, demograph-
ics, safety blood results and outcomes.11 Data from TIER.
Net were used to determine ART status (naïve vs.
experienced) of potentially eligible patients.
• The National Institute for Communicable Diseases’
GERMS-SA surveillance program is a laboratory-based
surveillance program which captures all cases of dissemi-
nated cryptococcal disease that have occurred in South Africa
during 2005–2013 diagnosed in NHLS laboratories and other
laboratories serving private hospitals, and the military
and mining sector. From this database, we identiﬁed patients
with prior, concurrent, and incident cryptococcal disease.
• Where available, we examined individual patient charts and
pharmacy records to obtain information on ﬂuconazole
treatment for those who screened positive for CrAg.
Unique health identiﬁers were not available on all
patient records from the datasets described above. Therefore,
the databases were matched using probabilistic linkage based
on all available patient identiﬁers. Matching was facilitated by
STATA 13.1 and Fine Grained Record Linkage (FRIL)
software.12
Definitions
Screening-Eligible Patient
A patient was deﬁned as eligible for screening if he or
she was $18 years old at the time a CD4 count was obtained,
ART-naïve, had no prior or concurrent cryptococcal disease,
and presented with a CD4 count ,100 cells per microliter for
the ﬁrst time to a Western Cape provincial outpatient clinic
during September 1, 2012–August 31, 2013 (hereafter, referred
to as a qualifying CD4 count). Patients who presented to care at
a hospital were excluded because the screening guidelines were
intended for outpatient settings. Additionally, patients present-
ing to care at a Cape Town city clinic (as opposed to a Western
Cape provincial clinic) were also excluded because Cape Town
city clinics did not initiate CrAg screening until August 2013.
CrAg Screened
Serum CrAg LA test was performed #7 days before to
#30 days after the qualifying CD4 count was obtained. The
7-day window before CD4 test was chosen to account for any
time delays and discrepancies between the time a sample is
obtained and the time it takes to get processed in the lab and
for reporting to occur.
Prior Cryptococcal Disease
Disseminated cryptococcal disease (including CM and
cryptococcemia) diagnosed before the date of qualifying
CD4 count.
Concurrent Cryptococcal Disease
Disseminated cryptococcal disease diagnosed at the
time of or #14 days from the date of qualifying CD4 count.
Incident Cryptococcal Disease
Disseminated cryptococcal disease diagnosed.14 days
after the date of qualifying CD4 count.
Fluconazole Treated
A patient who received ﬂuconazole (any dose and any
duration) after the date of the positive serum CrAg result.
Data Analysis
Categorical variables were analyzed using the x2 test
and medians of continuous variables were analyzed using the
Wilcoxon rank-sum test. The level of signiﬁcance was set at
a = 0.05.
RESULTS
Proportion Screened and Prevalence of
Cryptococcal Antigenemia
There were 9192 HIV-positive adults who presented to
care with a CD4 count ,100 cells per microliter for the ﬁrst
time during September 1, 2012–August 31, 2013 in the
Western Cape. In total, 4797 patients (52.2%) were excluded
from analysis as screening ineligible for the following
reasons: 1795 (19.5%) were ART-experienced at the time
the CD4 count was obtained, 2872 (31.5%) presented to care
at a district hospital or tertiary care, 899 (9.8%) presented at
a Cape Town city clinic, and 105 (1.1%) had prior or
concurrent disseminated cryptococcal disease (categories
not mutually exclusive). Although not the focus of this
analysis, notably, the CrAg prevalence in the hospitalized
patients was 3.4% and among ART-experienced patients
was 2.8%.
The resulting cohort eligible for screening included
4395 patients. The median age was 34 years (interquartile
range: 29–41) and 50.1% (n = 2204) were woman. Twenty-
seven percent (n = 1170) of those eligible had a CrAg test
done 7 days before to 30 days after their CD4 count test (our
predeﬁned criterion for being considered CrAg screened).
Prevalence of CrAg positivity among CrAg-screened patients
was 2.1% (n = 24/1170). The proportion of patients screened
increased during the study period (Fig. 1), from 15.9% in
September 2012, the ﬁrst month of the screening program, to
36.6% in August 2013, the end of the ﬁrst year of the
screening program. If the screening window was limited to
FIGURE 1. Proportion of eligible patients with screening CrAg
test by month in the Western Cape Province, September
2012–August 2013.
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#7 days before to #14 days after the CD4 count test, 17.5%
(n = 767) of patients would be considered screened.
Incidence of Cryptococcal Disease Among
Screening-Eligible Patients
There were 9 (0.8%) incident cases of disseminated
cryptococcal disease among the 1170 patients screened for
CrAg compared with 49 (1.5%) incident cases among the 3225
patients not screened (P = 0.07) (Fig. 2). All 9 cases in the
screened group occurred in patients with a negative CrAg
screening result. Among these 9 patients, the time from CD4 test
date to date of diagnosis of cryptococcal disease ranged from 35
to 497 days (median of 103 days) (Table 1). Three of 9 patients
had been prescribed ART before the date they developed
cryptococcal disease. None of the 24 screened, CrAg-positive
patients developed cryptococcal disease. Fluconazole treatment
data were available for 13 of 24 CrAg-positive patients; 9 were
treated with ﬂuconazole following testing. The median time
between CD4 date and date of diagnosis of cryptococcal disease
among the 49 patients who were not screened and developed
cryptococcal disease was 155 days (range: 17–589).
A higher proportion of CrAg-screened patients were
prescribed ART (72.9%, 853/1170) compared with those
were not screened (48.3%, n = 1556/3225) (P , 0.001). The
median time from CD4 testing to ART initiation was 24 days
for those screened compared with 33 days for those not
screened (P , 0.001).
Disseminated Cryptococcal Disease in the
Western Cape Among All PLHIV
There were 421 patients with disseminated cryptococcal
disease in the Western Cape during the study period; of these,
74 did not have a CD4 count available for analysis and were
therefore excluded. Of the remaining 317 patients, 80.7% (n =
280) had a CD4 count of ,100 cells per microliter, of whom
5.7% (n = 16) had had prior cryptococcal disease. Another
45.4% (n = 127) had concurrent cryptococcal disease (within
2 weeks of their CD4 count). Finally, 48.9% (n = 137)
presented with incident disease.
DISCUSSION
In this evaluation of a large public sector CrAg
screening program in the Western Cape, South Africa, we
found that only 1 in 4 eligible patients were screened during
the ﬁrst year of the program, though the proportion of eligible
patients screened increased to 1 in 3 toward the end of the
evaluation period. Among patients who were eligible for
screening, the incidence of cryptococcal disease among those
screened for CrAg was approximately half that of those not
screened (0.8% vs. 1.5%).
The Western Cape was the ﬁrst province to adopt CrAg
screening province-wide in South Africa. Before screening
program initiation, the 2 screening strategies were considered:
laboratory-based reﬂex testing vs. provider-initiated testing. In
a laboratory-based reﬂex testing strategy, the CrAg screening
test is not dependent on a provider’s order; instead, it is
reﬂexively (routinely) performed in the laboratory on any blood
sample with CD4 count,100 cells per microliter. Although the
same blood sample is used for CrAg testing, reﬂexive testing
would also reduce time to result since an additional patient visit
and a blood draw for CrAg testing would not be required. The
disadvantages of laboratory-based reﬂexive testing include
potentially “wasted” testing of ineligible patients, such as those
already receiving ART, and those getting repeated CD4 testing,
patients not returning for CD4 result and therefore not receiving
their CrAg test result and any necessary antifungal treatment,
and clinicians potentially not knowing how to act on a test they
did not speciﬁcally order.
The provider-initiated screening approach was ulti-
mately chosen for several reasons. Logistically, laboratories
TABLE 1. Characteristics of Patients Eligible for Cryptococcal
Antigen (CrAg) Screening, Western Cape, South Africa,
September 1, 2012–August 31, 2013
CrAg Screened
(n = 1151)
Not Screened
(n = 3225) P
Female, n (%) 555 (48.2) 1649 (51.3) 0.02
Median age, yrs (IQR) 35.2 (29.6–41.4) 34.3 (29.3–40.8) 0.05
Incidence of disseminated
cryptococcal disease,
n (%)
9 (0.8) 49 (1.5) 0.07
Median time to CM, d (IQR) 103 (69–119) 155 (70–262) 0.48
ART started, n (%) 853 (74.1) 1556 (48.3) ,0.001
Median time to ART among
those who started ART,
d (IQR)
24 (16–36) 33 (18–62) ,0.001
CrAg, cryptococcal antigen; CM, cryptococcal meningitis; ART, antiretroviral
treatment.
FIGURE 2. Incidence of disseminated cryptococcal disease
among patients screened and not screened for CrAg, Western
Cape Province, September 1, 2012–August 31, 2013.
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in the Western Cape were willing to assume the additional
burden of CrAg testing by request. The LFA was unavailable
at the time of program initiation, meaning that an additional
tube of blood was required for CrAg testing with LA (LFA
can be performed on remnant blood from CD4 test but LA
cannot) and generated the additional cost associated with
drawing an extra tube of blood on every patient before the
CD4 count was available. Additionally, provider-initiated
screening could be quickly implemented by sending out
a routine circular updating clinicians on the new guidance,
whereas high-level coordination between the Department of
Health and the NHLS would have been required for reﬂexive
laboratory-based testing. It should be noted that once the
provider-initiated screening strategy was chosen, no formal
training related to CrAg screening was held at the provincial or
local levels; each clinic manager was responsible for informing
clinic staff about the new screening recommendations.
Thus, despite the rapid implementation of provider-
initiated screening in the Western Cape, a low proportion of
eligible patients were screened in the absence of formal
training of clinical providers. Even if the proportion of
screened patients increased further in the second and third
years of the program with more training, it is unlikely to reach
optimal levels because it relies on individual providers to
remember to order the test. From other medical interventions
such as antenatal syphilis screening among pregnant women,
it is known that screening interventions that depend on
individual providers can be poorly implemented.13 In con-
trast, reﬂex laboratory testing for CrAg conducted on the
same blood sample used for the CD4 test, piloted in 2 other
South African provinces, resulted in a .95% CrAg screening
rate for patients with CD4 count ,100 cells per microliter.14
It is imperative that a high proportion of the eligible
population be screened for CrAg for the screening program
to be effective; missed screening opportunities result in
additional cases of disseminated cryptococcal disease, adding
to the morbidity, mortality, and substantial healthcare and
other economic and social costs.
Another notable ﬁnding from the provider-initiated
approach to CrAg screening is the delay from CD4 testing
to CrAg screening. We found that while nearly one quarter of
patients were screened within a 30-day window from the
qualifying CD4 count, only 17% were screened within 2
weeks. Ideally, screening should take place within 2 weeks to
prevent CM, given that the median duration of cryptococcal
antigenemia in the serum before onset of meningitis is
approximately 3 weeks.6 Patients presenting to care with
CD4 counts below 100 cells per microliter are severely
immunosuppressed and their risk of developing opportunistic
infections and dying increases with each week they are not
started on ART.15 Provider-initiated screening potentially
delays ART initiation, especially for the large group of
patients who screen CrAg-negative (.95%), because it may
require an additional patient visit and a blood draw for
screening. There is also potential risk of loss to follow up with
the additional time and economic burden from having an
extra clinic visit for CrAg testing.
We found a CrAg prevalence of approximately 2% in
our study. This is lower than the 6% prevalence reported in
a previous study that retrospectively tested stored serum
samples of patients presenting to a large ART clinic in the
Western Cape.7 It is possible that certain clinics have a higher
prevalence than others, and a province-wide evaluation
results in lower numbers than a study at a single clinic, or
because the previous study was conducted 8 years earlier,
when the landscape of HIV care and treatment was different
in South Africa. A prevalence of 2% is comparable to that
reported in other studies on the prevalence of antigenemia in
southern Africa.14 A study examining the cost-effectiveness
of a cryptococcal screening program found that screening for
CrAg is cost-effective when the prevalence is as low as
0.6%.16 Additionally, we found that CrAg prevalence was
substantial in other groups not included in recommendations
for CrAg screening (3.4% among inpatients and 2.8% among
ART-experienced patients). Including these groups in screen-
ing recommendations could have an even larger impact on
cryptococcal disease prevention. All cases of disseminated
cryptococcosis in the screened group occurred among those
who screened CrAg negative. This is likely due to 2 reasons.
First, the LA test used for detecting serum CrAg in the program
is less sensitive than the LFA.17 It is possible that some patients
who truly had antigenemia were not identiﬁed by screening
and therefore developed cryptococcal disease. Second, only 3
out of 9 patients who developed cryptococcal disease were
started on ART immediately after screening. Patients who
screen negative for CrAg but for whom ART is not initiated
remain profoundly immunosuppressed and remain at risk for
cryptococcal disease. This ﬁnding highlights the importance of
combining CrAg screening with prompt initiation of ART to
reduce the burden of cryptococcal disease. A recently pub-
lished randomized controlled trial conducted in Tanzania and
Zambia found that among severely immunosuppressed pa-
tients, a 28% reduction in mortality occurred when CrAg
screening was combined with ART adherence support.18
Fluconazole uptake among those who screened CrAg
positive was lower than desired. We could not ﬁnd any
evidence of receipt of ﬂuconazole in about 30% of patients
for whom we had records available. The ﬁnding of low
uptake of ﬂuconazole may have to do with poor patient
follow-up, poor provider compliance with guidelines, lack of
availability of ﬂuconazole at some clinics, or poor record
keeping (ﬂuconazole was prescribed but not documented).
This ﬁnding underscores the importance of patient and
provider education, supply chain management, good docu-
mentation, and the need for adherence to all elements of the
screening and treatment cascade for effective prevention of
disseminated cryptococcal disease. The higher proportion of
ART initiation and shorter time to initiation in the screened
group likely reﬂects better overall care that this group
receives. It is also possible that screening for CrAg is a tool
to retain patients in care and that patients who get screened
are also more likely to return to care to get started on ART.
Finally, we found that of all evaluable cases of
disseminated cryptococcal disease among PLHIV in the
Western Cape during the study period, approximately half
occurred in patients at least 2 weeks after they presented with
a low CD4 count. These cases could potentially have been
prevented with a combination of CrAg screening and
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treatment, prompt ART initiation, and retention of patients in
care. An additional one-third of the burden of cryptococcal
disease was seen in patients who presented with CM at the
time of CD4 count testing. CrAg screening would not have
prevented disease because they already have disseminated
disease. Efforts to improve earlier HIV diagnosis and linkage
to care would likely address this portion of the burden of
cryptococcal disease.
There are several limitations to this evaluation. First,
whereas the Western Cape is the only province in South
Africa to have implemented a unique patient identiﬁer, the
identiﬁer was not available on all datasets and duplicate
identiﬁers still occurred for some patients. Therefore, we
relied on probabilistic methods for further matching based on
a limited number of variables to match patients from the
different data sources. Incomplete matching may have
resulted in an underestimate of the proportion of the patients
screened. However, we made every attempt to optimize
matching by liberalizing matching criteria, such as allowing
for misspelling of patient names and transposition of birth
dates; we manually cross-checked matches of thousands of
records that were not perfectly matched. Second, we may not
have captured all incident cases of cryptococcal disease. The
GERMS SA cryptococcal disease surveillance program is
a laboratory-based surveillance system, which theoretically
captures most cases of cryptococcal disease in the country.
However, it is possible that we missed some cases of
cryptococcal disease, though there is no reason to believe that
the surveillance system would have preferentially captured either
CrAg screened or non–CrAg-screened patients. Third, because
this is not a randomized controlled trial, we cannot conclude that
the reduced incidence of cryptococcal disease in the screened
group was speciﬁcally owing to the screening program. We
found that a signiﬁcantly higher proportion of those screened
started ART compared with those who were not screened. It is
possible that the difference in incidence is also partly explained
by better ART services and retention in care in those clinics or
with those providers who also performed CrAg screening.
In March 2015, the National Department of Health
incorporated CrAg screening into the national consolidated
HIV guidelines, along with other changes, which include
initiating ART with a CD4 count threshold of 500 cells per
microliter, an increase from the previous threshold of 350
cells per microliter.19 Inclusion of CrAg screening in the
South African national guidelines may help make more
clinicians aware of the guidance and may result in increased
screening rates, though this is yet to be evaluated.
In conclusion, provider-initiated screening, as imple-
mented in the Western Cape, did not reach optimal screening
coverage in the ﬁrst year of the program. Public sector
programs implementing CrAg screening should consider
reﬂexive lab-based CrAg screening to optimize screening if
laboratory infrastructure can support this. Other provinces
have successfully piloted reﬂexive screening recently. In
addition, LFA should be considered in place of LA for CrAg
testing because of its high sensitivity, lower cost, and ease of
use. If provider-initiated screening is to be continued in the
Western Cape or considered by other countries, it should be
paired with systematic and intensive training of clinical staff
to improve screening coverage and subsequent patient
management. Sites initiating screening programs should
consider putting a thorough monitoring and evaluation system
in place before initiation to document screening program
performance. In addition to CrAg screening and preemptive
treatment, it is essential to increase HIV testing and early
diagnosis and improve ART initiation rates in order to
address the burden of cryptococcal disease.
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